Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: A retrospective study

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Kim, Hyo Sup ^a   Park, Bo Kyoung ^a   Kim, Seong koo ^a,b   Han, Seung Beom ^a,b   Lee, Jae Wook ^a,b   Lee, Dong Gun ^b   Chung, Nack Gyun ^a,b   Cho, Bin ^a,b   Jeong, Dae Chul ^a,b   Kang, Jin Han ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Antibiotic resistance; Child; Multidrug resistance; Neutropenia; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; QUINOLONE DERIVATIVE; THIENAMYCIN DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; CHILD; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; MORTALITY; MORTALITY RATE; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; NONHUMAN; OBSERVATIONAL STUDY; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FEVER; MICROBIOLOGY; NEUTROPENIA; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADOLESCENT; AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FEVER; FLUOROQUINOLONES; HUMANS; MALE; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; THIENAMYCINS;

EID: 85024094380     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2597-0     Document Type: Article

References (35)

1. Bodey GP, Rodriguez V, Chang HY, Narboni. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer. 1978;41:1610-22.
2. Todeschini G, Vinante F, Benini F, Perini A, Pasini F, Cetto G. Gram-negative septicemia in patients with hematologic malignancies. Eur J Cancer Clin Oncol. 1984;20:327-31.
3. Lee JH, Kim SK, Kim SK, Han SB, Lee JW, Lee DG, et al. Increase in antibiotic-resistant gram-negative bacterial infections in febrile neutropenic children. Infect Chemother. 2016;48:181-9.
4. Cattaneo C, Casari S, Bracchi F, Signorini L, Ravizzola G, Borlenghi E, et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis. 2010;42:324-32.
5. Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96:e1-3.
6. Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, et al. P. aeruginosa Bloodstream infections among hematological patients: an old or new question? Ann Hematol. 2012;91:1299-304.
7. Zhang Q, Smith JC, Zhu Q, Guo Z, MacDonald NE. A five-year review of Pseudomonas aeruginosa bacteremia in children hospitalized at a single center in southern China. Int J Infect Dis. 2012;16:e628-32.
8. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56-93.
9. Grisaru-Soen G, Lerner-Geva L, Keller N, Berger H, Passwell JH, Barzilai A. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. Pediatr Infect Dis J. 2000;19:959-63.
10. Yang MA, Lee J, Choi EH, Lee HJ. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes. J Korean Med Sci. 2011;26:612-8.
11. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010;95:1612-5.
12. Fergie JE, Shema SJ, Lott L, Crawford R, Patrick CC. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin Infect Dis. 1994;18:390-4.
13. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26:220-52.
14. Turner D, Cheifetz I. Shock. In: Kliegman RM, Stanton BF, St. Geme JW, Schor NF, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016. p. 516-28.
15. Sreedharan R, Avner E. Renal failure. In: Kliegman RM, Stanton BF, St. Geme JW, Schor NF, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016. p. 2539-47.
16. Suchy F. Fulminant hepatic failure. In: Kliegman RM, Stanton BF, St. Geme JW, Schor NF, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016. p. 1966-8.
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
18. Todeschini G, Franchini M, Tecchio C, Meneghini V, Pizzolo G, Veneri D, et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis. 1998;3:99-104.
19. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501-9.
20. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001;33:1859-64.
21. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2):S146-55.
22. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998;17:701-8.
23. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003;47:2756-2764.
24. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145(9):1621-9.
25. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745-51.
26. Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am J Health Syst Pharm. 2007;64:2462-6.
27. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60:247-57.
28. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 1997;41:1127-33.
29. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS 2nd. Monotherapy or combination therapy? The Pseudomonas aeruginosa Conundrum. Pharmacotherapy. 2011;31:598-608.
30. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379-82.
31. Paul M, Soares-Weiser K, Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111.
32. Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104:205-12.
33. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57:112-8.
34. Georges B, Conil JM, Dubouix A, Archambaud M, Bonnet E, Saivin S, et al. Risk of emergence of Pseudomonas aeruginosa resistance to β-lactam antibiotics in intensive care units. Crit Care Med. 2006;34:1636-41.
35. Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children. Microb Drug Resist. 2015;21:244-51.